Patents Assigned to TAKEDA VACCINES, INC.
-
Patent number: 11964008Abstract: The present disclosure relates to methods for inactivating a Zika virus which can be used in vaccines and immunogenic compositions. The present disclosure also relates to a method for determining the completeness of inactivation of an arbovirus preparation.Type: GrantFiled: September 13, 2022Date of Patent: April 23, 2024Assignee: Takeda Vaccines, Inc.Inventors: Jill A. Livengood, Holli Giebler, Hansi Dean, Tatsuki Satou, Raman Rao, Jackie Marks, Mark Lyons, Asae Shintani, James Gifford, Sushma Kommareddy
-
Patent number: 11931399Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.Type: GrantFiled: December 12, 2022Date of Patent: March 19, 2024Assignee: Takeda Vaccines, Inc.Inventors: Dan T. Stinchcomb, Claire Kinney, Richard M. Kinney, Jill A. Livengood
-
Publication number: 20240076631Abstract: The present invention relates to a method for removing host cell DNA from a sample comprising infectious viral particles and host cell DNA by anion exchange chromatography in the presence of at least one of a non-ionic surfactant, a sugar and a protein and to a method for purifying recombinant infectious viral particles from a host cell culture employing such an anion exchange chromatography step.Type: ApplicationFiled: February 26, 2021Publication date: March 7, 2024Applicant: Takeda Vaccines, Inc.Inventors: Yock LEE, Jia LOH, Joseph SANTANGELO
-
Patent number: 11826415Abstract: The present invention relates to vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to methods of conferring protective immunity to Norovirus infections in a human subject.Type: GrantFiled: June 15, 2021Date of Patent: November 28, 2023Assignee: Takeda Vaccines, Inc.Inventors: Charles Richardson, Thomas S. Vedvick, Thomas R. Foubert, William Tino
-
Publication number: 20230355748Abstract: The invention relates to a single unit dose of a dengue vaccine composition and methods and uses for preventing dengue disease and methods for stimulating an immune response to all four dengue virus serotypes in a subject or subject population. The unit dose of a dengue vaccine composition includes constructs of each dengue serotype, such as TDV-1, TDV-2, TDV-3 and TDV-4, at various concentrations in order to improve protection from dengue infection.Type: ApplicationFiled: January 4, 2023Publication date: November 9, 2023Applicant: Takeda Vaccines, Inc.Inventor: Derek WALLACE
-
Publication number: 20230324404Abstract: The present invention is directed to a method, i.e. an immunoassay, for determining the presence and/or the amount of anti-zika Anti-ZIKV #1 virus antibodies, i.e. zika virus-specific antibodies in a sample. Therefore, the present invention is directed to a microsphere complex comprising a microsphere coupled to a zika virus like particle, as well as to a kit comprising said microsphere complex and an amount of reporter antibody that binds to the zika virus like particle. The present invention further relates to a method for determining an antibody correlate of protection against zika virus infection for a zika virus vaccine. Moreover, the present invention is directed to a method for diagnosing the protection of a human or non-human subject against a zika virus infection.Type: ApplicationFiled: May 19, 2021Publication date: October 12, 2023Applicant: Takeda Vaccines, Inc.Inventors: Erick PEREZ-GUZMAN, Eduardo NASCIMENTO, Hansi DEAN, Ralph BRAUN
-
Patent number: 11730802Abstract: The present disclosure relates to Zika virus vaccines and immunogenic compositions having one or more antigens from a Zika virus (e.g., a Zika virus clonal isolate, a non-human cell adapted Zika virus, etc.), and methods of treatments and uses thereof.Type: GrantFiled: November 5, 2018Date of Patent: August 22, 2023Assignee: Takeda Vaccines, Inc.Inventors: Jill A Livengood, Hansi Dean, Htay Htay Han, Raman Rao, Jackie Marks, Gary Dubin, Laurence De Moerlooze, Hetal Patel, Sushma Kommareddy
-
Publication number: 20230233628Abstract: The invention relates to a unit dose of a dengue vaccine composition and methods and uses for preventing dengue disease and methods for stimulating an immune response to all four dengue virus serotypes in a subject or subject population. The unit dose of a dengue vaccine composition includes constructs of each dengue serotype, such as TDV-1, TDV-2, TDV-3 and TDV-4, at various concentrations in order to improve protection from dengue infection.Type: ApplicationFiled: August 9, 2022Publication date: July 27, 2023Applicant: Takeda Vaccines, Inc.Inventor: Derek WALLACE
-
Patent number: 11701420Abstract: The present invention relates to single dose parenteral vaccine compositions comprising mixtures of monovalent Norovirus virus-like particles. Methods of conferring protective immunity against Norovirus infections in a human subject by administering such compositions are also disclosed.Type: GrantFiled: June 5, 2020Date of Patent: July 18, 2023Assignee: Takeda Vaccines, Inc.Inventors: Charles Richardson, Thomas R. Foubert, Robert F. Bargatze, Paul Mendelman
-
Patent number: 11701421Abstract: Embodiments herein relate to compositions and methods for stabilizing Flaviviruses. In certain embodiments, compositions and methods disclosed herein concern stabilizing live, attenuated or unattenuated (e.g. live whole) flaviviruses. Other embodiments relate to compositions and methods for reducing degradation of live, attenuated or unattenuated flaviviruses. Other embodiments relate to improved formulations for prolonging stabilization of live attenuated or unattenuated Flaviviruses during manufacturing, storage, accelerated storage and transport. Yet other embodiments relate to uses of compositions disclosed herein in kits for transportable applications and methods.Type: GrantFiled: October 5, 2020Date of Patent: July 18, 2023Assignee: TAKEDA VACCINES, INC.Inventors: Jill Ann Livengood, Linda Marie Strange, Steven Michael Erb
-
Publication number: 20230204567Abstract: The present disclosure relates to a method for determining the potency of an antigen sample such as a vaccine antigen sample. The present disclosure is also related to a method for monitoring the potency of a vaccine antigen during the production process including purifying, inactivating and formulating the vaccine antigen and to a method for producing a virus vaccine. Further, the present disclosure relates to vaccines obtainable by the methods disclosed. In certain embodiments of the present invention the antigen sample is a zika virus antigen sample.Type: ApplicationFiled: March 19, 2021Publication date: June 29, 2023Applicant: Takeda Vaccines, Inc.Inventors: Jill LIVENGOOD, Michael JOHNSON, James GIFFORD, Tawnya NEAD, Mark LYONS, Jackie MARKS
-
Publication number: 20230181682Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.Type: ApplicationFiled: December 12, 2022Publication date: June 15, 2023Applicants: TAKEDA VACCINES INC., THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARYInventors: Dan T. STINCHCOMB, Claire KINNEY, Richard M. KINNEY, Jill A. LIVENGOOD
-
Publication number: 20230183655Abstract: The present invention relates to a method for removing host cell DNA from a sample comprising infectious viral particles and host cell DNA by anion exchange chromatography in the presence of at least one of a non-ionic surfactant, a sugar and a protein and to a method for purifying recombinant infectious viral particles from a host cell culture employing such an anion exchange chromatography step.Type: ApplicationFiled: February 26, 2021Publication date: June 15, 2023Applicant: Takeda Vaccines, Inc.Inventors: Yock Ann LEE, Jia Vern LOH, Joseph David SANTANGELO
-
Publication number: 20230149538Abstract: The invention relates to a method for preventing dengue disease and hepatitis A in a subject or subject population by simultaneously administering a unit dose of a dengue vaccine composition and a hepatitis A vaccine on the same day. The unit dose of a dengue vaccine composition includes constructs of each dengue serotype, such as TDV-1, TDV-2, TDV-3 and TDV-4, at various concentrations in order to improve protection from dengue infection.Type: ApplicationFiled: July 20, 2022Publication date: May 18, 2023Applicant: Takeda Vaccines, Inc.Inventor: Derek WALLACE
-
Patent number: 11648304Abstract: The present disclosure relates to Zika virus vaccines and immunogenic compositions having one or more antigens from a Zika virus (e.g., a Zika virus clonal isolate, a non-human cell adapted Zika virus, etc.), and methods of manufacture, formulation, testing, and uses thereof.Type: GrantFiled: November 5, 2018Date of Patent: May 16, 2023Assignee: Takeda Vaccines, Inc.Inventors: Jill A. Livengood, Holli Giebler, Whitney Baldwin, Hansi Dean, Claire Y. H. Kinney
-
Publication number: 20230145065Abstract: The present disclosure relates to methods for inactivating a Zika virus which can be used in vaccines and immunogenic compositions. The present disclosure also relates to a method for determining the completeness of inactivation of an arbovirus preparation.Type: ApplicationFiled: September 13, 2022Publication date: May 11, 2023Applicant: TAKEDA VACCINES, INC.Inventors: Jill A. LIVENGOOD, Holli Giebler, Hansi Dean, Tatsuki Satou, Raman Rao, Jackie Marks, Mark Lyons, Asae Shintani, James Gifford, Sushma Kommareddy
-
Patent number: 11590221Abstract: The invention relates to a unit dose of a dengue vaccine composition and methods and uses for preventing dengue disease and methods for stimulating an immune response to all four dengue virus serotypes in a subject or subject population. The unit dose of a dengue vaccine composition includes constructs of each dengue serotype, such as TDV-1, TDV-2, TDV-3 and TDV-4, at various concentrations in order to improve protection from dengue infection.Type: GrantFiled: September 5, 2019Date of Patent: February 28, 2023Assignee: Takeda Vaccines, Inc.Inventor: Derek Wallace
-
Publication number: 20220357312Abstract: The present invention relates to methods for determining affinity, binding kinetics and/or concentration of an antibody or of an antibody mixture specific for a virus using virus-like particles (VLPs) and/or live viruses or inactivated viruses attached to biosensors. Further, the present invention relates to the VLPs and live or inactivated viruses attached to biosensors and methods for producing them.Type: ApplicationFiled: October 2, 2020Publication date: November 10, 2022Applicant: Takeda Vaccines, Inc.Inventors: Isamu TSUJI, Hansi DEAN, Michael EGAN
-
Patent number: 11478541Abstract: The present disclosure relates to methods for inactivating a Zika virus which can be used in vaccines and immunogenic compositions. The present disclosure also relates to a method for determining the completeness of inactivation of an arbovirus preparation.Type: GrantFiled: November 5, 2018Date of Patent: October 25, 2022Assignee: Takeda Vaccines, Inc.Inventors: Jill A. Livengood, Holli Giebler, Hansi Dean, Tatsuki Satou, Raman Rao, Jackie Marks, Mark Lyons, Asae Shintani, James Gifford
-
Publication number: 20220332800Abstract: The present invention provides isolated monoclonal antibodies, or antigen-binding portions thereof, that bind to ZIKV glycoproteins, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies, or antigen-binding portions thereof, according to the present invention are useful for inhibiting or neutralizing ZIKV activity, thus providing a means of treating or preventing ZIKV infection in humans. The antibodies, or antigen-binding portions thereof, according to the present invention may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.Type: ApplicationFiled: September 20, 2019Publication date: October 20, 2022Applicant: Takeda Vaccines, Inc.Inventors: Subash C. DAS, Isamu TSUJI, Jill A. LIVENGOOD, Hansi DEAN